Entries by admin

Epidemiological and survival analysis of triple-negative breast cancer cases in a retrospective multicenter study

/0 Comments/in /by

http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2016;volume=53;issue=3;spage=353;epage=359;aulast=Sarin;type=0 This is a retrospective study with data collected from breast cancer cases from five major Apollo Hospitals across India, as part of a biobanking process. One aspect of our study focused specifically on data from triple-negative breast cancer (TNBC) cases. The aim of this study was to analyze epidemiology, treatment options, and survival of […]

Sapien collaborates with Dr. Anjana Rao of La Jolla Institute

/0 Comments/in /by

It is a pleasure to be working again with Dr. Anjana Rao, Jugnu’s postdoc advisor from Dana Farber Cancer Institute & Harvard Medical School days. Anjana is now the Chair of La Jolla Institute of Allergy and Immunology with a joint appointment at UCSD.  Her lab’s work on Tet family of proteins and their regulation […]

Sapien Biosciences and OncoStem Diagnostics collaborate to launch CanAssist-Breast, a Breast cancer recurrence prediction test

/0 Comments/in /by

Hyderabad, November 10, 2016: Sapien Biosciences, a niche biotech venture committed to develop novel cutting-edge medical diagnostics backed by Apollo Hospitals Enterprise Limited announces its partnership with OncoStem Diagnostics, to launch “CanAssist-Breast”, a robust and cost-effective test to predict the risk of breast cancer recurrence in early stage hormone positive and Her2 negative Breast Cancer […]

Human medical waste to build biobanks

/0 Comments/in /by

http://www.journal.ijmio.com/index.php/ijmio/article/view/132 Jugnu Jain, Sreevatsa Natarajan, Soma Chatterjee India has a high disease burden and a large number of patients. There is a tremendous need for Indian biobanks to preserve Indian samples, to capture the great diversity of diseases to spur research into earlier, more precise diagnosis and better treatments for diseases plaguing India. This review […]

Sapien collaborates with Boston University to perform cost-benefit analysis of treatment paradigm in PCI Stent patients in the Indian healthcare system

/0 Comments/in /by

Sapien  is collaborating with Dr. Joglekar’s group  at Boston University  to mine Sapien’s cardiac patients database. Our goal is to jointly analyse patterns of usage of different stents, blood thinning medicines, co-medications, myPlatelet assay , follow-up visits and monitoring with an eye towards optimizing implementation of personalized treatment to improve patient outcomes. Over the last […]

Industry Internships for Motivated Biology-Based Graduate Students

/0 Comments/in /by

Jugnu Jain CEO at Sapien Biosciences & Saarum Sciences We offer 2 to 12 month research internships for bright diligent motivated graduate students in Biology, Biotech, Pharmacy, Bioinformatics, Health data analytics etc. The internships can be hands-on lab experience (molecular biology, cell biology, diagnostics, FACS etc.), or in medical data analysis, sample and clinical data […]

Our first paper on breast cancer is accepted for publication

/0 Comments/in , /by

Jugnu Jain CEO at Sapien Biosciences & Saarum Sciences “Epidemiological and survival analysis of triple negative breast cancer cases in a retrospective multicentre study” comprising 257 TNBC cases collated from across five cancer centres in India has been accepted for publication. It should be out in a few months. Next one summarizing data from >6500 […]

Breast cancer in low-income countries: India as a model

/0 Comments/in , /by

Abstract: Background: Developing countries contribute substantially to breast cancer mortality worldwide, as early-stage diagnosis and effective adjuvant therapies have decreased breast cancer-specific mortality in developed countries. Unfortunately, the costs of breast cancer screening programs and treatments limit translation of these results to developing nations. Methods: We retrospectively analyzed the tumor characteristics and modalities of management […]

ROS1 rearrangements occur in approximately 1% of patients with NSCLC

/0 Comments/in , , /by

The Promising Therapeutic Strategy against ALKoma and ROS1-positive Tumors It has recently been identified that crizotinib significantly inhibits the tumor cells with ALK-fusion genes or ROS1-rearranged driver genes which encode constitutive tyrosine kinase receptors. The emerging concept of lung cancer stem cells (CSCs) arises a question of the relationship between CSCs and ROS1 gene rearrangement. […]